ࡱ > 5 7 4 t
bjbj[[ ; 9 9 V " " " 8 Z n " 0 z " $ L J _ _ _ v _ _ _ _ P0 . _ 0 _ H 1 . H _ H _ ( _ _ H :
Supporting Information (5):
Suppl. Table 1: Distribution of the analyzed primary and metastatic tissue of the 23 patients in the western blot study.
Suppl. Table 2: Distribution of the analyzed primary and metastatic tissue of the 18 patients in the immunohistochemistry study.
Suppl. Fig. 1: Treatment response of GEP-NEN cell lines to nutlin-3 treatment. BON, QGP-1, LCC-18 and KRJ-I cell lines were treated with nutlin-3, siomycin A ADDIN EN.CITE ADDIN EN.CITE.DATA [17] and everolimus for 24 and 72 hours. Only KRJ-I cells responded to the treatment.
Suppl. Fig 2: KEGG pathview visualization of altered gene expression of cell cycle related genes after 60h nutlin-3a treatment. A high number of positive cell cycle regulators (such as MCM genes, genes of CDKs and cyclins) was downregulated (green) after nutlin-3a treatment. The upregulation (red) of MDM2, GADD45 and CDKN1A (p21) demonstrate a typical p53 response. Grey indicates no differential expression; white denotes the gene is not included in the panel.
Suppl. Table 3: All significantly altered transcripts after 60h nutlin-3a 5M treatment. Associated Pathways: STAT, PI3K, RAS, MAPK, Wnt, Notch, TGFB, DNA repair, Apop=apoptosis, TXmisReg=transcriptional misregulation, CC=cell cycle, TGFB=TGF-beta, ChromMod= chromatin remodeling, HH=Hedgehog; bolded genes indicate a FDR<0.05.
PAGE \* MERGEFORMAT1
k :
I
e S
ѮѮјp[H[[H %h|o h/ B*CJ aJ mH ph sH (h|o h/ 5B*CJ aJ mH ph sH #h|o h/ CJ aJ mH nH sH u+j6
h|o h/ CJ UaJ mH sH +j h|o h/ CJ UaJ mH sH %j h|o h/ CJ UaJ mH sH h|o h/ 5CJ aJ mH sH h|o h/ CJ aJ mH sH (h|o h/ 5B*CJ$ aJ$ mH ph sH h|o h/ mH sH :
;
T
U
V
p
q
r
s
t
$a$ dh gd/
$dh a$gd/ gd/ S
T
U
V
W
l
m
n
o
s
t
´ j h1 UmH nH u h/ mH nH uh1 j h1 Uh/ h1 mH sH hL5 h/ B*mH ph sH h3? h/ CJ aJ mH sH
9 0P 1h:p1 . A!"#$n% 6
D Briest20151737[17]1737173717Briest, F.Berg, E.Grass, I.Freitag, H.Kaemmerer, D.Lewens, F.Christen, F.Arsenic, R.Altendorf-Hofmann, A.Kunze, A.Sanger, J.Knosel, T.Siegmund, B.Hummel, M.Grabowski, P.Department of Gastroenterology, Infectious Diseases, Rheumatology CC13, Medizinische Klinik 1, CBF, Germany.
Department of Chemistry and Biochemistry, Freie Universitat (FU) Berlin, Germany.
Institute of Pathology, CBF, Charite - Universitatsmedizin Berlin, Germany.
Department of General and Visceral Surgery, Zentralklinik Bad Berka GmbH, Germany.
Institute of Biology, Humboldt-Universitat Berlin, Germany.
Institute of Pathology, CCM, Charite-Universitatsmedizin Berlin, Germany.
Department of General, Visceral and Vascular Surgery, Friedrich-Schiller-Universitat (FSU) Jena, Germany.
Institute of Pathology, Bad Berka, Germany.
Institute of Pathology, Ludwig-Maximilians-Universitat (LMU), Munich, Germany.
Department of Internal Oncology and Hematology, Zentralklinik Bad Berka GmbH, Germany.FOXM1: A novel drug target in gastroenteropancreatic neuroendocrine tumorsOncotargetOncotargetOncotargetOncotargetOncotargetOncotarget8185-996102015/03/242015Apr 101949-2553 (Electronic)
1949-2553 (Linking)25797272http://www.impactjournals.com/oncotarget/index.php?journal=oncotarget&page=article&op=view&path[]=3600NLMeng6
D Briest20151737[17]1737173717Briest, F.Berg, E.Grass, I.Freitag, H.Kaemmerer, D.Lewens, F.Christen, F.Arsenic, R.Altendorf-Hofmann, A.Kunze, A.Sanger, J.Knosel, T.Siegmund, B.Hummel, M.Grabowski, P.Department of Gastroenterology, Infectious Diseases, Rheumatology CC13, Medizinische Klinik 1, CBF, Germany.
Department of Chemistry and Biochemistry, Freie Universitat (FU) Berlin, Germany.
Institute of Pathology, CBF, Charite - Universitatsmedizin Berlin, Germany.
Department of General and Visceral Surgery, Zentralklinik Bad Berka GmbH, Germany.
Institute of Biology, Humboldt-Universitat Berlin, Germany.
Institute of Pathology, CCM, Charite-Universitatsmedizin Berlin, Germany.
Department of General, Visceral and Vascular Surgery, Friedrich-Schiller-Universitat (FSU) Jena, Germany.
Institute of Pathology, Bad Berka, Germany.
Institute of Pathology, Ludwig-Maximilians-Universitat (LMU), Munich, Germany.
Department of Internal Oncology and Hematology, Zentralklinik Bad Berka GmbH, Germany.FOXM1: A novel drug target in gastroenteropancreatic neuroendocrine tumorsOncotargetOncotargetOncotargetOncotargetOncotargetOncotarget8185-996102015/03/242015Apr 101949-2553 (Electronic)
1949-2553 (Linking)25797272http://www.impactjournals.com/oncotarget/index.php?journal=oncotarget&page=article&op=view&path[]=3600NLMeng